CA2168261A1 - Antagonistes du facteur de croissance hemopoietique - Google Patents

Antagonistes du facteur de croissance hemopoietique

Info

Publication number
CA2168261A1
CA2168261A1 CA002168261A CA2168261A CA2168261A1 CA 2168261 A1 CA2168261 A1 CA 2168261A1 CA 002168261 A CA002168261 A CA 002168261A CA 2168261 A CA2168261 A CA 2168261A CA 2168261 A1 CA2168261 A1 CA 2168261A1
Authority
CA
Canada
Prior art keywords
leu
ile
arg
lys
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002168261A
Other languages
English (en)
Inventor
Mathew Alexander Vadas
Angel Francisco Lopez
Mary Frances Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2168261A1 publication Critical patent/CA2168261A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formes modifiées et variantes de facteurs de croissance hématopoïétique (HGF) pouvant servir d'antagonistes dirigés contre les facteurs de croissance hématopoïétique natifs correspondants, et leur application à l'amélioration des effets aberrants dus aux molécules natives. Un facteur de croissance hématopoïétique (HGF) modifié est caractérisé en ce qu'il se présente sous forme non glycosylée et en ce qu'il comporte une séquence d'acides aminés à l'intérieur d'une première hélice alpha , dans laquelle un ou plusieurs acides aminés découverts présents dans ladite première hélice alpha et présentant des propriétés acides ou semblables à celles des acides sont substitués par un reste d'acide aminé basique. Les HGF préférés sont le facteur stimulant les colonies de granulocytes macrophages (GM-CSF), l'interleukine (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9 et IL-10, le G-CSF et l'érythropoïétine (EPO).
CA002168261A 1993-07-28 1994-07-28 Antagonistes du facteur de croissance hemopoietique Abandoned CA2168261A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPM018693 1993-07-28
AUPM0186 1993-07-28
AUPM4772 1994-03-30
AUPM477294 1994-03-30

Publications (1)

Publication Number Publication Date
CA2168261A1 true CA2168261A1 (fr) 1995-02-09

Family

ID=25644508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168261A Abandoned CA2168261A1 (fr) 1993-07-28 1994-07-28 Antagonistes du facteur de croissance hemopoietique

Country Status (7)

Country Link
US (1) US5939063A (fr)
EP (1) EP0715633A4 (fr)
JP (1) JPH09501154A (fr)
CA (1) CA2168261A1 (fr)
NZ (1) NZ269766A (fr)
SG (1) SG52238A1 (fr)
WO (1) WO1995004075A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703052B2 (en) * 1995-06-23 1999-03-11 Bresagen Limited Haemopoietic growth factor antagonists and uses therefor
AUPN378095A0 (en) 1995-06-23 1995-07-20 Bresagen Limited Haemopoietic growth factor antagonists and uses therefor
WO1997048728A1 (fr) * 1996-06-20 1997-12-24 Koster, Henk, Wilhelmus Peptides derives de l'il-6 et du recepteur de l'il-6 presentant une activite agoniste ou antagoniste vis-a-vis de l'il-6
WO1998010792A1 (fr) * 1996-09-11 1998-03-19 Prendergast Patrick T Therapie a but immunitaire
WO2001025277A1 (fr) * 1999-10-07 2001-04-12 Maxygen Aps Polypeptides antagonistes a chaine unique
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
CA2498319A1 (fr) * 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
JP2008527981A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 治療目的および診断目的のためにパラメーターにより選択されたｇｍ−ｃｓｆ、ｉｌ−３、ｉｌ−４、ｉｌ−５、ならびにそのキメラ
SG11201600294QA (en) * 2013-07-17 2016-02-26 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591427A (en) * 1979-10-07 1997-01-07 Medvet Science Pty. Ltd. Human Interleukin-3(Il-3) variants and their use to promote or antagonize IL-3-mediated processes
AU615550B2 (en) * 1988-04-21 1991-10-03 Medvet Science Pty. Ltd. Human gm-csf variants
EP0810285A3 (fr) * 1989-08-14 1998-07-08 Gist-Brocades B.V. Mutants de l'interleukine-3 humaine

Also Published As

Publication number Publication date
US5939063A (en) 1999-08-17
WO1995004075A1 (fr) 1995-02-09
NZ269766A (en) 1998-01-26
EP0715633A4 (fr) 1997-11-19
SG52238A1 (en) 1998-09-28
EP0715633A1 (fr) 1996-06-12
JPH09501154A (ja) 1997-02-04

Similar Documents

Publication Publication Date Title
CA2002607C (fr) Facteur stimulatoire letal naturel
Park et al. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness
EP0888122B1 (fr) PROTEINE HYBRIDE A INTERFERON-alpha ET FRAGMENT Fc D'IMMUNOGLOBULINE A LIAISON ASSUREE PAR PEPTIDE NON IMMUNOGENE
US7361738B2 (en) Megakaryocyte stimulating factors
CA1341489C (fr) Famille de facteurs de croissance hematopoietiques provenant de primates
US20100041586A1 (en) Method of improving efficacy of biological response-modifying proteins and the exemplary muteins
AU2500392A (en) Hybrid cytokines
CA2168261A1 (fr) Antagonistes du facteur de croissance hemopoietique
US6171824B1 (en) Hybrid cytokines
DE60037648T2 (de) Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
AU690128B2 (en) Haemopoietic growth factor antagonists
PT667872E (pt) Interleucina-6 mutante com actividade biologica melhorada em relacao a da interleucina 6 selvagem
Kato Characteristics of natural and recombinant human interleukin 2
DE60310434T2 (de) Interferon nachahmende peptide und rekombinante proteine
JPH06501009A (ja) ナチュラルキラー刺激因子
MXPA00001208A (en) Chemical modification of proteins to improve biocompatibility and bioactivity
MXPA06001037A (en) A method of improving efficacy of biological response-modifying proteins and the exemplary muteins
IE871727L (en) Novel family of primate il3-like hematopoietic growth¹factors.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead